Rights issue in Targovax ASA (NO) — NOK 175 million

Carnegie acted as joint bookrunner fully underwritten rights issue of approximately NOK 175 million. Targovax is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock greater clinical benefits in cancer patients by deploying its multifunctional platforms to target key immune regulators and oncogenic drivers.
December 2021.